Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Naunyn Schmiedebergs Arch Pharmacol
2007 Dec 01;3764:285-93. doi: 10.1007/s00210-007-0201-7.
Show Gene links
Show Anatomy links
The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.
Kracke GR
,
Stoneking SP
,
Ball JM
,
Tilghman BM
,
Washington CC
,
Hotaling KA
,
Johnson JO
,
Tobias JD
.
???displayArticle.abstract???
A functional link between the cannabinoid and opioid receptor pathways has been proposed based on data showing that cannabinoid effects can be blocked by opioid receptor antagonists and that cannabinoids can bind to opioid receptors. To explore this link in more detail at the receptor level, we tested the hypothesis that cannabinoids directly activate or modulate mu opioid receptor function. The G-protein coupled mu opioid receptor, MOR-1, and its effector, the G-protein activated potassium channel, GIRK2 (Kir3.2), were expressed together in Xenopus oocytes and potassium currents measured using the two-electrode voltage clamp technique. The specific mu receptor agonist DAMGO activated potassium currents in oocytes expressing the mu receptor that were fully inhibited by the mu receptor antagonist, naloxone. The endogenous cannabinoid, anandamide, and the synthetic cannabinoid, WIN 55,212-2, had no direct effects on potassium currents in the oocytes expressing the mu receptor. The cannabinoids also had no effect on the magnitude of the potassium currents activated by DAMGO or on the desensitization kinetics of MOR-1 in the continued presence of DAMGO. Both WIN 55,212-2 and anandamide activated cannabinoid CB1 receptors when co-expressed with GIRK2 in the oocytes. We conclude that neither anandamide nor WIN 55,212-2 directly activate or modulate mu opioid receptor function in oocytes and that interactions of cannabinoids with mu opioid receptors are likely to be indirect.
Akinshola,
Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP.
1999, Pubmed,
Xenbase
Akinshola,
Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP.
1999,
Pubmed
,
Xenbase
Allen,
Regional differences in naloxone modulation of Delta(9)-THC induced Fos expression in rat brain.
2003,
Pubmed
Berrendero,
Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol.
2002,
Pubmed
Bloom,
9-nor-9beta-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine.
1977,
Pubmed
Coda,
The hypothesis that antagonism of fentanyl analgesia by 2-chloroprocaine is mediated by direct action on opioid receptors.
1997,
Pubmed
Consroe,
The perceived effects of smoked cannabis on patients with multiple sclerosis.
1997,
Pubmed
Demuth,
Cannabinoid signalling.
2006,
Pubmed
Fisyunov,
Cannabinoids modulate the P-type high-voltage-activated calcium currents in purkinje neurons.
2006,
Pubmed
Gray,
Cell biology. A last GASP for GPCRs?
2002,
Pubmed
Henry,
Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes.
1995,
Pubmed
,
Xenbase
Herzberg,
The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain.
1997,
Pubmed
Hirota,
Ketamine: its mechanism(s) of action and unusual clinical uses.
1996,
Pubmed
Ibrahim,
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.
2005,
Pubmed
Iversen,
Cannabinoids: a real prospect for pain relief?
2002,
Pubmed
Kathmann,
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors.
2006,
Pubmed
Kumar,
Pharmacological actions and therapeutic uses of cannabis and cannabinoids.
2001,
Pubmed
Manzanares,
Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
1999,
Pubmed
Manzanares,
Pharmacological and biochemical interactions between opioids and cannabinoids.
1999,
Pubmed
Mason,
Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
1999,
Pubmed
McAllister,
Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system.
1999,
Pubmed
,
Xenbase
Navarro,
Functional interaction between opioid and cannabinoid receptors in drug self-administration.
2001,
Pubmed
Niederhoffer,
The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.
2003,
Pubmed
Oye,
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
1992,
Pubmed
Pugh,
Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord.
1995,
Pubmed
Quasha,
Determination and applications of MAC.
1980,
Pubmed
Rios,
mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis.
2006,
Pubmed
Rodriguez,
Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.
2001,
Pubmed
Schoffelmeer,
Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
2006,
Pubmed
Smith,
Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
1998,
Pubmed
Tanda,
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
1997,
Pubmed
Thorat,
Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice.
1994,
Pubmed
Tulunay,
Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats.
1981,
Pubmed
Vacca,
Boosting effect of morphine on alcohol drinking is suppressed not only by naloxone but also by the cannabinoid CB1 receptor antagonist, SR 141716.
2002,
Pubmed
Vaysse,
Modulation of rat brain opioid receptors by cannabinoids.
1987,
Pubmed
Viganò,
Molecular and cellular basis of cannabinoid and opioid interactions.
2005,
Pubmed
Williams,
Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol.
2006,
Pubmed
Williams,
Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.
2002,
Pubmed
Wilson,
Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs.
1975,
Pubmed
Zhang,
Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters.
1996,
Pubmed
,
Xenbase
